



EISAI LAUNCHES ANTIEPILEPTIC DRUG FYCOMPA® IN HONG KONG
FIRST REGION IN ASIA TO GAIN ACCESS TO NEW FIRST-IN-CLASS THERAPY

Eisai Co., Ltd. (Headquarters: Tokyo)

[Notes to editors]

1. About Epilepsy

Epilepsy is a medical condition that produces seizures, affecting a variety of mental and physical functions. A patient is considered to have epilepsy after two or more unprovoked seizures. A seizure occurs when a brief, strong surge of electrical activity affects part or all of the brain. An individual can have various symptoms, from convulsions and loss of consciousness, to some that are not always recognized as seizures, such as blank staring, lip smacking, or jerking movements of arms and/or legs.

Epilepsy can develop at any age and 0.5% to 2% of people will develop epilepsy during their lifetime. Epilepsy reportedly affects nearly 1 million people in Japan, 2.4 million people in Europe (G5), 2.2 million people in the United States, and more than 50 million people worldwide. Epilepsy constitutes an area in which there are still significant unmet medical needs, with partial-onset epilepsy accounting for approximately 55% of all epilepsy cases in Hong Kong, and from 20% to 40% of patients living with partial epilepsy in that country not achieving seizure freedom despite therapy with antiepileptic drugs (AEDs).

2. About Fycompa (Perampanel)

Fycompa, a novel chemical enti(ep)14.4eFye.ent(4.2(ssio)4(i)1nti(e.e(s)-4()J]Jsn g thno)-5)n

Study 305

•The 50% responder rates compared to placebo for the ITT population were: 33.3% ($p=0.0018$) and 33.9% ($p=0.0006$) in the 8 mg and 12 mg perampanel/day groups, respectively, versus 14.7% with placebo.

•The median percentage changes in seizure frequency for the ITT population shown were: 8 mg = -30.5% ($p=0.0008$), 12 mg = -17.6% ($p=0.0105$), and placebo = -9.7%.

•